Illumina, Inc. (ILMN)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Illumina's New Connected Multiomics Platform Set to Boost Its Stock
ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Illumina (ILMN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina (ILMN) Surges 3.3%: Is This an Indication of Further Gains?
Illumina (ILMN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade
Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Illumina, Inc. (ILMN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Illumina, Inc. ( ILMN ) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 9:20 AM EST Company Participants Jacob Thaysen - CEO & Director Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC Okay. Good morning, everybody.
Illumina, Inc. (ILMN) Q3 2025 Earnings Call Transcript
Illumina, Inc. ( ILMN ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Conor Noel McNamara - VP of Investor Relations Jacob Thaysen - CEO & Director Ankur Dhingra - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Douglas Schenkel - Wolfe Research, LLC Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Daniel Leonard - UBS Investment Bank, Research Division Patrick Donnelly - Citigroup Inc., Research Division Mason Carrico - Stephens Inc., Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Jack Meehan - Nephron Research LLC Daniel Brennan - TD Cowen, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Presentation Operator Good day, ladies and gentlemen.
Compared to Estimates, Illumina (ILMN) Q3 Earnings: A Look at Key Metrics
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Illumina (ILMN) Beats Q3 Earnings and Revenue Estimates
Illumina (ILMN) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.14 per share a year ago.
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
